HIPEC (hyperthermic intraperitoneal chemotherapy) is a novel therapeutic modality implemented in selected cases of genital malignancies in the females, mainly in patients with intraperitoneal cancer dissemination. The procedure is an integral part of surgical treatment, because it is done during radical tumor excision or cytoreductive surgery. A prerequisite for HIPEC is excision of all visible tumor foci of over 5 mm. This facilitates penetration of cytostatics to the peritoneum and destruction of persisting viable cancer cells. We present preliminary assessment of effectiveness of cytoreductive surgery combined with intraperitoneal perfusion chemotherapy under hyperthermia in 18 patients with late-stage ovarian cancer, peritoneal mesothelioma and disseminated uterine sarcoma. In our material, in 2 cases only surgery preceding HIPEC consisted in freeing of adhesions and excision of isolated intraperitoneal implants of less than 1 cm. All other patients underwent extensive cytoreduction. In all cases, the HIPEC procedure was performed by closed technique after completion of cytoreductive surgery. Cytostatics used included cisplatin (75 mg/m²) and adriamycin (30 mg/m²), which, depending on diagnosis, were administered alone or combined. After surgery, the predominating complication experienced by over 83% of the patients were nausea and vomiting of varying severity. To date, HIPEC procedure has not won a secure position in the treatment of ovarian cancer, both due to required proper equipment and disposable sets of drains, but mainly because of lack of unequivocally defined and optimal for a particular patient timing of execution. It has not been settled, whether such an optimal moment is completion of first-line adjuvant or neoadjuvant chemotherapy or recurrence of disease after another line of treatment. An indispensable prerequisite for implementation of intraperitoneal chemotherapy is maximal cytoreduction of tumor mass. Based on initial experiences we may state that the HIPEC procedure is a valuable adjunct for other established therapeutic modalities in oncology on the condition of proper, multidisciplinary qualification for the procedure.